Literature DB >> 1707382

Gamma-interferon production in response to hepatitis B core protein and its synthetic peptides in patients with chronic hepatitis B virus infection.

T Wakita1, S Kakumu, Y Tsutsumi, K Yoshioka, A Machida, M Mayumi.   

Abstract

The nucleocapsid of hepatitis B virus (HBV) is an efficient immunogen in activating T cells to produce interferon-gamma (IFN-gamma) in patients with chronic HBV infection. We investigated hepatitis B core antigen (HBcAg)-specific T cell recognition, which seems to be implicated in the pathogenesis of chronic liver disease. IFN-gamma production by peripheral-blood mononuclear cells of patients with chronic HBV infection [25 patients with chronic active hepatitis (CAH) and 14 asymptomatic carriers of HBV (ASCs)] was measured by an enzyme-linked immunosorbent assay. P19 polypeptide, which is derived from recombinant HBcAg particle (rHBcAg), increased IFN-gamma production in patients with CAH, but its effect was weaker than that of rHBcAg. P19 had no stimulating effect on T cells from ASCs. The fine specificity of T cell recognition of HBcAg was examined using 8 kinds of synthetic peptides. T cells from the patients who responded against P19 polypeptide recognized the sites within the common sequences of HBcAg and HBeAg (p72-90, P90-99, P108-122 and P126-146). These results suggest that HBcAg and P19 are cross-reactive at the T cell level, and that these T cells recognize the sites within the common sequences of HBcAg and HBeAg in HBV-infected patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1707382     DOI: 10.1159/000200490

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  1 in total

1.  CTL escape mutations of core protein are more frequent in strains of HBeAg negative patients with low levels of HBV DNA.

Authors:  Hossein Sendi; Marjan Mehrab-Mohseni; Saeid Shahraz; Helene Norder; Seyed-Moayed Alavian; Babak Noorinayer; Mohammad R Zali; Paul Pumpens; Herbert L Bonkovsky; Lars O Magnius
Journal:  J Clin Virol       Date:  2009-09-12       Impact factor: 3.168

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.